Papilledema in Children With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Case Series

Documenti analoghi

• Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis
  di: Cindy L. Williams, et al.
  Pubblicazione: (2025)
• Real World Adverse Effects of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis Ages 6–11 Years
  di: Rebecca S. Pettit, et al.
  Pubblicazione: (2025)
• Current State of Pharmacogenomic Implementation Into Care for Persons With Cystic Fibrosis
  di: Emma M. Tillman, et al.
  Pubblicazione: (2025)
• Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis
  di: Sara Kümmerli, et al.
  Pubblicazione: (2026)
• Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase‐1 in Children With Cystic Fibrosis
  di: Senthilkumar Sankararaman, et al.
  Pubblicazione: (2025)